Cellular macromolecules and low-molecular-weight compounds in hypoxic viable cells

Cellular macromolecules and low-molecular-weight compounds in hypoxic viable cells refers to the collective set of molecular substrates targeted by hypoxia-activated prodrugs (HAPs) and bioreductive agents [1]. These therapeutic and diagnostic agents are designed to be selectively activated in the low-oxygen (hypoxic) environments characteristic of solid tumors [3]. Once reduced by intracellular enzymes like nitroreductases or cytochrome P450 reductases, they form highly reactive intermediates—such as free radicals or alkylating mustards—that covalently bind to essential cellular components [1, 3]. These components include macromolecules like DNA, RNA, and proteins, as well as low-molecular-weight compounds like glutathione [3, 10]. The resulting molecular damage, particularly DNA cross-linking and strand breaks, induces apoptosis in hypoxic cells, which are often resistant to conventional chemotherapy and radiation [1]. This approach allows for the selective targeting of the most aggressive and treatment-resistant portions of a tumor [1, 3]. Common drugs interacting with these targets include evofosfamide and tirapazamine, which exploit the unique redox environment of hypoxic cells to achieve tumor-selective toxicity [1]. Monitoring these interactions often involves hypoxia biomarkers such as pimonidazole adducts or PET imaging with nitroimidazole tracers [3].

Other names

Hypoxic cell molecular targetsBioreductive drug substratesDNA and proteins in hypoxic cellsHypoxia-activated prodrug targets

Hypoxia-activated bioreductive alkylation and radical-mediated damage to DNA and proteins.